[Untitled]

Between 1984 and 1993, monoclonal antibodies (MAbs) radiolabelled with 131I were administered into the CSF of 52 patients with neoplastic meningitis (meningosis) with progressive disease despite active conventional therapy. Selection of MAbs was based on immunoreactivity with patients' tumour and lack of binding to normal central nervous system (CNS) tissue.